ArmaGen is a privately held, clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders.
Location: United States, California, Calabasas
Total raised: $17M
Investors 2
| Date | Name | Website |
| - | Mitsui Glo... | mitsui-glo... |
| - | Takeda Ven... | takeda.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.12.2012 | Series A | $17M | - |
Mentions in press and media 3
| Date | Title | Description |
| 17.06.2014 | ArmaGen Receives Notice of Allowance for U.S. Patent Covering Novel Investigational Therapy for Hunter Syndrome | Strengthens Extensive Intellectual Property for Therapies that Cross the Blood-Brain Barrier CALABASAS, Calif.–(BUSINESS WIRE)–June 17, 2014– ArmaGen, a privately held biotechnology company focused on developing revolutionary therapies for ... |
| 03.12.2012 | ArmaGen Technologies Raises $17M in Series A Funding | ArmaGen Technologies, a Santa Monica, CA-based developer of brain-penetrating recombinant protein therapeutics, has raised $17m in Series A funding. The round was led by Boehringer Ingelheim Venture Fund, with participation from Shire plc, ... |
| 30.11.2012 | ArmaGen Technologies Inks $17M Series A | LOS ANGELES, CA, ArmaGen Technologies, Inc. today announced the closing of a $17 million Series A financing to support the development of brain-penetrating recombinant protein therapeutics. The lead investor is Boehringer Ingelheim Ventur... |